Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476).

Autor: James ND; Institute of Cancer Research, London, UK., Clarke NW; The Departments of Surgery & Urology, The Christie & Salford Royal Hospitals, Manchester, UK., Cook A; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Ali A; The Christie NHS Foundation Trust, Manchester, UK., Hoyle AP; Salford Royal HS Foundation Trust, Manchester, UK., Attard G; UCL Cancer Institute, University College London, London, UK., Brawley CD; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Chowdhury S; Guy's, King's, & St. Thomas' Hospitals, and Sarah Cannon Research Institute, London, UK., Cross WR; St James University Hospital, Leeds, UK., Dearnaley DP; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK., de Bono JS; Institute of Cancer Research, London, UK., Diaz-Montana C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Gilbert D; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Gillessen S; Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland., Gilson C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.; Royal Marsden Hospital, London, UK., Jones RJ; Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, UK., Langley RE; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Malik ZI; Radiotherapy Unit, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Liverpool, L7 8YA, UK., Matheson DJ; School of Allied Health and Midwifery, Faculty of Education, Health and Wellbeing, University of Wolverhampton, Wolverhampton, WS1 3BD, UK., Millman R; (PPI) c/o MRC CTU at UCL, London, UK., Parker CC; Uro-Oncology Unit, Royal Marsden Hospital and Institute of Cancer Research, Sutton, UK., Pugh C; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Rush H; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.; Guys and St Thomas' NHS Foundation Trust, London, UK., Russell JM; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.; Beatson West of Scotland Cancer Centre, Glasgow, UK., Berthold DR; Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland., Buckner ML; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Mason MD; Cardiff University, School of Medicine, Cardiff, UK., Ritchie AWS; Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK., Birtle AJ; Rosemere Cancer Centre, Lancashire Teaching Hospitals & University of Manchester, University of Central Lancashire, Lancashire, UK., Brock SJ; University Hospital Dorset, Bournemouth, UK., Das P; Department of Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK., Ford D; City Hospital, Cancer Centre at Queen Elizabeth Hospital, Birmingham, UK., Gale J; Portsmouth Hospitals University Trust, Portsmouth, UK., Grant W; Gloucestershire Oncology Centre, Cheltenham General Hospital, Cheltenham, UK., Gray EK; Musgrove Park Hospital, Taunton, UK., Hoskin P; Mount Vernon Cancer Centre, Northwood, UK., Khan MM; Department of Oncology Castle Hill Hospital, Hull, UK.; Scarborough General Hospital, Scarborough, UK., Manetta C; Brighton and Sussex University Hospitals NHS Trust, Brighton, UK., McPhail NJ; Department of Clinical Oncology, Raigmore Hospital, Inverness, UK., O'Sullivan JM; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK., Parikh O; Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Trust, Preston, UK., Perna C; Royal Surrey NHS Foundation Trust, Guildford, UK., Pezaro CJ; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK., Protheroe AS; Oxford University Hospitals NHS Foundation Trust, Oxfordshire, UK., Robinson AJ; Sussex Cancer Centre, Brighton, UK., Rudman SM; Guys and St Thomas' NHS Foundation Trust, London, UK., Sheehan DJ; Royal Devon & Exeter NHS Foundation Trust, Exeter, UK., Srihari NN; Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK., Syndikus I; Radiotherapy Unit, The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, Liverpool, L7 8YA, UK., Tanguay JS; Velindre Cancer Centre, Cardiff, UK., Thomas CW; Kent Oncology Centre, Maidstone, Kent, UK., Vengalil S; University Hospital North Midlands NHS Trust, Staffordshire, UK., Wagstaff J; Swansea University and the South West UK Cancer Centre, Swansea, UK., Wylie JP; The Christie NHS Foundation Trust, Manchester, UK., Parmar MKB; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK., Sydes MR; MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, UCL, London, UK.

Publikováno v: International journal of cancer [Int J Cancer] 2022 Aug 01; Vol. 151 (3), pp. 422-434. Date of Electronic Publication: 2022 May 16.